Analyst: Genmab share price may double

In an analysis, Jyske Bank estimates that Genmab's stock price does not reflect the potential of the company's pipeline, although it highlights one large risk within this share.
Photo: Lars Møller / Genmab / PR
Photo: Lars Møller / Genmab / PR
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN

Genmab has struggled so far in 2021, but certain signs indicate the share may be regaining its momentum, according to an analysis from the Danish bank Jyske Bank.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading